Oncology

Opioids in Neuropathic Pain Treatment

Neuropathic Pain – The Case for Opioid Therapy

Allen S.C.

Author affiliations

Royal Berkshire Hospital, Reading, UK

Keywords: Neuropathic painOpioidsRational polypharmacyOxycodone

Related Articles for ""
Oncology 2008;74:76–82
https://doi.org/10.1159/000143224

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Opioids in Neuropathic Pain Treatment

Published online: August 28, 2008
Issue release date: August 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

For many patients, neuropathic pain (NeP) is arguably more difficult to control than nociceptive or ‘normal’ pain. We also now recognise the great burden that NeP has on the lives of patients – it is not only a matter of treating pain in isolation, but managing all of the issues that affect the patient’s quality of life. Until relatively recently we have had little understanding of the pathophysiology causing NeP and have relied on the secondary effects of non-analgesic drugs as the mainstays of treatment. Greater understanding of the pathophysiology of NeP has led to more appropriate therapy and an increased use of multiple drug therapy – ‘rational polypharmacy’. Traditional opinions concerning the treatment of NeP have been challenged and it is because of this that the use of opioids in NeP has been re-evaluated. Opioids will never replace tricyclic antidepressants and anti-epileptic drugs as first-line therapy for NeP. However, they are now fully established as effective and useful second- or third-line drugs. Many patients in the past have been potentially undertreated as a result of our inertia to use opioids. The case for opioid therapy in NeP has been firmly established.

© 2008 S. Karger AG, Basel



Related Articles:

References

  1. Smith T, Chong MS: Neuropathic pain. Hosp Med 2000;61:760–766.
    External Resources
  2. Karlsten R, Gordh T: How do drugs relieve neurogenic pain? Drugs Aging 1997;11:398–412.
    External Resources
  3. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, Coderre T, Morley-Foster PK, Stinson J, Boulanger A, Peng P, Finlay GA, Taenzer P, Squire P, Dion D, Cholkan A, Gilani A, Gordon A, Henry J, Jovey R, Lynch M, Mailis-Gagnon A, Panju A, Rollman GB, Velly A, Canadian Pain Society: Pharmacological management of chronic neuropathic pain – Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13–21.
    External Resources
  4. Johnson PC, Doll SC, Cromey DW: Pathogenesis of diabetic neuropathy. Ann Neurol 1986;19:450–457.
    External Resources
  5. Amos AF, McCarthy DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med1997;14(suppl 5):S1–S85.
    External Resources
  6. Davies M, Brophy S, Williams R, Taylor A: The prevalence, severity and impact of painful diabetic neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518–1522.
    External Resources
  7. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ: Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004;19:976–982.
    External Resources
  8. Abbot CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, Hann AW, Hussein A, Jackson N, Johnson KE, Ryder CH, Torkington R, Van Ross ER, Whalley AM, Widdows P, Williamson S, Boulton AJM: The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based cohort. Diabet Med2002;19:377–384.
    External Resources
  9. Kost RG, Straus SE: Postherpetic neuralgia – Pathogenesis, treatment and prevention. N Engl J Med 1996;335:32–42.
    External Resources
  10. Bennett MI: The LANNS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147–157.
    External Resources
  11. Bennett MI, Smith BH, Torrance N, Potter J: The S-LANNS score for identifying pain of predominantly neuropathic origin: validation of use in clinical and postal research. J Pain 2005;6:149–158.
    External Resources
  12. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin J, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Scluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E: Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29–36.
    External Resources
  13. Freynhagen R, Baron R, Gockel U, Tölle TR: painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911–1920.
    External Resources
  14. Bennett MI, Attal N, Backonja MM, Baron R, Bouhassira D, Freynhagen R, Scolz J, Tölle TR, Wittchen HU, Jensen TS: Using screening tools to identify neuropathic pain. Pain 2007;127:199–203.
    External Resources
  15. Hall GC, Carroll D, Parry D, McQuay HJ: Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain 2006;122:156–162.
    External Resources
  16. Chong MS, Bajwa ZH: Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage 2003;25:S4–S11.
    External Resources
  17. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell CM, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM: Advances in neuropathic pain. Arch Neurol 2003;60:1524–1534.
    External Resources
  18. Sindrup S, Jensen T: Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389–400.
    External Resources
  19. Schmader KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350–354.
    External Resources
  20. Gureje O, Von Korff M, Simon GE, Gater R: Persistent pain and well being: a World Health Organization study in primary care. JAMA 1998;280:147–151.
    External Resources
  21. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A: Peripheral neuropathic pain – A multidimensional burden for patients. Eur J Pain 2001;5:379–389.
    External Resources
  22. Oster G, Harding G, Dukes E, Edelsburg J, Cleary PD: Pain, medication use and health-related quality of life in older persons with postherpetic neuralgia: results from a population based survey. J Pain 2005;6:356–363.
    External Resources
  23. Rowbotham MC, Reisner-Keller LA, Fields HL: Both intravenous lidocaine and morphine reduce pain of postherpetic neuralgia. Neurology 1991;41:1024–1028.
    External Resources
  24. Dellemijn PLI, van Dujin H, Vanneste JAL: Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998;16:220–229.
    External Resources
  25. Leung A, Wallace MS, Ridgeway B, Yaksh T: Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain 2001;91:177–187.
    External Resources
  26. Foley KM: Opioids and chronic pain therapy. N Engl J Med 2003;348:1279–1281.
    External Resources
  27. Namaka M, Gramlich CR, Ruhlen D, Melanson M, Sutton I, Major J: A treatment algorithm for neuropathic pain. Clin Ther 2004;26:951–979.
    External Resources
  28. Auret K, Schug SA: Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem. Drugs Aging 2005;22:641–654.
    External Resources
  29. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D: Survey of chronic pain in Europe: prevalence, impact on daily life and treatment. Eur J Pain 2006;10:287–233.
    External Resources
  30. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D: Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:2688–2689.
    External Resources
  31. Gilron I, Bailey RN, Tu D, Holden RR, Weaver D, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–1334.
    External Resources
  32. Dellemijn PLI, Vanneste JAL: Randomised double-blind active-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753–758.
    External Resources
  33. Terpening CM, Johnson WM: Methadone as an analgesic: a review of the risks and benefits. W V Med J 2007;103:14–18.
  34. Watson CP, Babul N: Efficacy of oxycodone in neuropathic pain. A randomised trial in postherpetic neuralgia. Neurology 1998;50:1837–1841.
    External Resources
  35. Raja SN, Haythornthwaite JA, Pappagello M, Clark MR, Trtavison TG, Sabeen S, Troykall TRM, Max MB: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015–1021.
    External Resources
  36. Gimbel JS, Richards P, Portenoy RK: Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial in painful diabetic neuropathy. Neurology 2003;60:927–934.
    External Resources
  37. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J: Controlled-release oxycodone relieves neuropathic pain: a randomised controlled trial in painful diabetic neuropathy. Pain 2003;105:71–78.
    External Resources
  38. Baillie SP, Bateman DN, Coates PE, Woodhouse KW: Age and the pharmacokinetics of morphine. Age Aging 1989;18:258–262.
    External Resources
  39. Gourlay GK, Plummer JL, Cherry DA: Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain 1995;61:375–381.
    External Resources
  40. Warfield CA: Controlled-release morphine tablets in patients with chronic cancer pain: a narrative review of controlled clinical trials. Cancer 1998;82:2299–2306.
    External Resources
  41. Ross FB, Smith MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73:151–157.
    External Resources
  42. Benziger DP: IASP 8th World Congress on Pain (abstract No 223). Seattle, IASP Press, 1996.
  43. Kaiko RF, Benziger DP, Fitzmartin RD, Burke BE, Reder RF, Goldenheim PD: Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52–61.
    External Resources
  44. Mucci-LoRosso P, Berman BS, Silberstein PT, Citron Ml, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF: Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel group study. Eur J Pain 1998;2:239–249.
    External Resources
  45. Levy MH: Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 2001;5(suppl A):113–116.
    External Resources
  46. Riley J, Ross JR, Rutter D, Wells, AU, Goller K, du Bois R, Welsh K: No pain relief from morphine? Support Cancer Care 2006;14:56–64.
    External Resources
  47. Watson CP, Watt-Watson JH, Chipman ML: Chronic noncancer pain and the long term utility of opioids. Pain Res Manag 2004;9:19–24.
    External Resources
  48. Hempenstall K, Nurmiko TJ, Johnson RW, A’Hern RP, Rice ASC: Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2(7):628–644.
  49. Lesser H, Sharma U, La Moreaux L, Poole RM: Pregabalin relieves symptoms of painful diabetic neuropathy: a randomised controlled trial. Neurology 2004;63:2104–2110.
    External Resources
  50. Harati Y, Gooch C, Swenson M, Eldelman S, Greene D, Raskin P, Donofrio P, Cornblath D, Sachdeo R, Siu CO, Kamin M: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998;50:1842–1846.
    External Resources
  51. Gilron I, Watson CP, Cahill CM, Moulin DE: Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265–275.
    External Resources
  52. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005;118:289–305.
    External Resources
  53. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, Sampaio C, Sindrup S, Wiffen P, EFNS Task Force: EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153–1169.

Article / Publication Details

First-Page Preview
Abstract of Opioids in Neuropathic Pain Treatment

Published online: August 28, 2008
Issue release date: August 2008

Number of Print Pages: 7
Number of Figures: 3
Number of Tables: 0

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2008, Vol.74, Suppl. 1

August 2008

Article

Recommend This
TOP